Focus: Tenza is a pre-revenue biotechnology company developing a novel platform to reprogram symbiotic bacteria from the human microbiome to deliver medicines directly to target organs, currently focused on gastroenterology. The company operates as a venture-stage innovator with a differentiated cell-therapy approach in an emerging microbiome therapeutics space.
Profile data last refreshed 10h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Tenza to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Tenza
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tenza's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo